Placebo response and cessation in binge eating disorder: A pooled analysis of two randomized parallel-group clinical trials.

About this resource

OBJECTIVE: This study aims to explore predictors and clinical correlates of placebo response and cessation in binge eating disorder (BED). METHOD: Data from two identically designed, randomized, placebo-controlled, parallel-group, and multicenter pharmacotherapy studies for adults with moderate to severe BED were pooled. RESULTS: Of 360 placebo recipients, 134 (37%) were responders and 53 (15%) achieved 4-week binge eating cessation. Placebo response and cessation were each associated with higher baseline disability scores but not with measures of BED symptomatology severity. Compared with placebo noncessation, placebo cessation was further associated with increased blood pressure at baseline and greater improvement in pulse and triglyceride levels at endpoint. DISCUSSION: Future clinical trial design for BED pharmacotherapy trials might consider disability level among participants to enhance signal detection. Cessation of binge eating with placebo might be associated with improvement in cardiovascular and metabolic variables, at least over the short term.

AuthorBlom, Thomas J.; Guerdjikova, Anna I.; McElroy, Susan L.
JournalEuropean eating disorders review : the journal of
Year2018

See also

Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders

Bulimia Nervosa (BN) and Binge Eating Disorder (BED) are some of the most common eating disorders (ED) in industrialized societies, characterized by uncontrolled binge eating and self-induced purging or other compensatory behaviours aiming to prevent body weight gain.

Read more

Pharmacotherapy of binge-eating disorder: A review

Objectives: The purpose of this article is to provide a comprehensive review of pharmacotherapy for binge eating disorder, including new therapeutic approaches such as centrally acting sympathomimetics, nootropics, lisdexamfetamine, and substance abuse treatment agents such as acamprosate, sodium oxybate, baclofen, and naltrexone.

Read more

Fact sheet: What is binge eating disorder?

Read more

Binge eating disorder pharmacotherapy clinical trails - Who is left out?

Objective: This report examined the characteristics of subjects interested in binge eating disorder (BED) pharmacotherapy trails who were ineligible for participation.

Read more

Help us improve!

Give us feedback!

We will continue throughout 2019 to update and improve the NEDC website and welcome any feedback you may have on the site.

Provide feedback